Ambrx Biopharma Inc. Appoints Janice Lu, M.D., Ph.D., as Chief Medical Officer
“I am delighted to welcome Janice Lu to the Ambrx team and look forward to leveraging her insight in breast oncology to continue to progress ARX788 through the clinic,” said Feng Tian, Ph.D., Chairman of the Board, President, and CEO of Ambrx. “Janice has been a valuable asset as a principal investigator for multiple Ambrx trials, including the Phase 1 ACE-Pan Tumor-01 and Phase 2 ACE-Breast-03 clinical trials, and is the ideal candidate to take the role of CMO at our company. I look forward to leaning on Janice’s expertise to further our current research and development efforts in the treatment of oncology.”
“I am impressed with the encouraging data from the ongoing clinical trials of ARX788 and Ambrx’s engineered precision biologics technology platform,” said Dr. Lu. “I am excited to begin working with Ambrx in this new capacity, assisting with the ongoing development of their clinical development pipeline and overseeing the clinical operations. I believe our consorted efforts will potentially provide therapeutic treatment options that are less toxic and highly targeted to patients suffering from breast, gastric, and other solid tumors.”
Dr. Lu has spent her career focused on managing the treatment of women with breast cancer. Prior to her role at Ambrx, Dr. Lu was a Clinical Professor of Medicine and Medical Director of the Breast Oncology Program at the Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center. Prior to her role at USC, Dr. Lu was an Associate Professor of Clinical Medicine in the Division of Hematology and Oncology at the University of California, Los Angeles. Dr. Lu, a board certified medical oncologist, began her career at SUNY Stony Brook where she served as the Director of Breast Medical Oncology for several years.
Dr. Lu received a M.D. from Peking University School of Medicine as well as a Ph.D. from Syracuse University focusing on epigenetics under the mentorship of Dr. David Allis (Rockefeller University). Dr. Lu completed her Hematology and Oncology Fellowship at New York University School of Medicine.
About Ambrx Biopharma Inc. (Ambrx)
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, Ambrx has clinical collaborations with multiple partners, for drug candidates generated using Ambrx technology. For more information, please visit www.ambrx.com.
This press release includes certain “forward-looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements may be identified by the words “anticipate,” believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “may,” “will,” “could,” “should,” “seek,” “potential” and similar expressions, and include, without limitation, express or implied statements regarding Ambrx’s beliefs and expectations regarding the advancement and potential benefits of its product candidates, clinical development and strategic plans. Forward-looking statements are based on Ambrx’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the continuing impact of the COVID-19 pandemic and other public health-related risks and events on Ambrx’s business, operations, strategy, goals and anticipated milestones; Ambrx’s ability to execute on its strategy including with respect to the timing of its R&D efforts, initiation of clinical trials and other anticipated milestones; risks associated with development of novel therapeutics, including potential delays in clinical trials and regulatory submissions and the fact that future clinical trial results may not be consistent with preliminary results or results from prior preclinical studies or clinical trials; Ambrx’s ability to fund operations as anticipated; and the additional risks and uncertainties set forth more fully under the caption “Risk Factors” in Ambrx’s Annual Report on Form 20-F filed with the United States Securities and Exchange Commission (SEC) on April 26, 2022, and elsewhere in Ambrx’s filings and reports with the SEC. Forward-looking statements contained in this press release are made as of this date, and Ambrx undertakes no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.
Source: Ambrx, Inc.